Pharma & biotech news
Israel's business and economic news in English, from the country's financial press. Hebrew headlines are translated; every story links to the publisher.

Surprise Departure: Teva's Chief Medical Officer Receives Alternative Offer and Leaves Immediately
Dr. Arik Yoez, who served as Teva's Chief Medical Officer for the past four years, has departed the company to accept another offer. CEO Richard Francis stated that Yoez is leaving Teva in a strong position for the next chapter.
Globes (Hebrew, translated) · 2 days ago · Teva Pharmaceutical Industries Ltd.

Teva to join Russell 1000 large-cap index
Teva Pharmaceutical will be included in the Russell 1000 index of large-cap US companies.
Globes · 3 days ago · Teva Pharmaceutical Industries Ltd.

Teva share to join leading US index soon
Teva will join the Russell 1000 index in December, which includes the 1,000 largest companies in the Russell indices in the US. Entry into the index is expected to drive demand for Teva shares.
Globes (Hebrew, translated) · 3 days ago · Teva

Teva CEO: We have evolved into a biopharma company
Teva CEO Richard Francis stated that the company is evolving into a biopharma company, with branded drugs expected to account for 25% of revenue by 2030, up from 9% in 2022.
Globes · 1 week ago · Teva Pharmaceutical Industries Ltd.

Teva CEO: 'The future looks especially promising; we are also looking at larger acquisitions'
Teva is raising its revenue target from innovative medicines to $6-7 billion by 2030 and shows growth in cash flow and product pipeline. The CEO Richard Francis said the company is looking at larger acquisitions despite past challenges.
Globes (Hebrew, translated) · 1 week ago · Teva Pharmaceutical Industries Ltd.

Teva again raises guidance as branded drugs lift revenue
Teva reported third-quarter revenue of $4.4 billion, beating analyst expectations of $4.2 billion, and non-GAAP earnings per share of $0.86, exceeding the consensus of $0.72.
Globes · 2 weeks ago · Teva Pharmaceutical Industries Ltd.

Teva's flagship drugs deliver positive quarter and improved revenue guidance
Teva Pharmaceutical reported revenues of $4.4 billion, beating analyst expectations on both top and bottom lines, and raised its full-year 2026 guidance.
Globes (Hebrew, translated) · 2 weeks ago · Teva Pharmaceutical Industries Ltd.

20% Surge in Half a Year: Pharma Sector Benefits from Free Fall in Chip Stocks
Following a sharp decline in semiconductor stocks due to rising interest rates and financing costs, investors have shifted to pharmaceutical stocks, which have reached new highs. Software and cybersecurity stocks also declined amid the market correction.
Globes (Hebrew, translated) · 1 month ago

Five things to know before the stock exchange opens for trading
The Tel Aviv Stock Exchange reopens after a difficult week. Teva will surge following FDA approval for a schizophrenia drug, while Alko will transfer 95 million shekels to Electra Real Estate.
Globes (Hebrew, translated) · 1 month ago · Teva Pharmaceutical Industries Ltd., Alko, Electra Real Estate Ltd.

Over 5x jump since the low: Teva's comeback
A decade after the crisis that removed Teva from its status as Israel's flagship stock, the pharmaceutical giant has completed a comeback. The company's market value in New York has reached $47.9 billion, making it again the highest-valued Israeli company on the local exchange.
Globes (Hebrew, translated) · 1 month ago · Teva Pharmaceutical Industries Ltd.

FDA Approval for Teva's Once-Monthly Schizophrenia Injection Weltruza Boosts Share Price
Teva announced FDA approval for Weltruza, a once-monthly injection for schizophrenia treatment, reaching a share price level not seen in a decade.
Globes · 1 month ago · Teva Pharmaceutical Industries Ltd.

Israeli company soared to a decade high and another lost ground
Teva's stock jumped to its highest price since 2016 following approval for a new schizophrenia drug. Citi Bank downgraded Nova, which has fallen over 40% from its June peak.
Globes (Hebrew, translated) · 1 month ago · Teva Pharmaceutical Industries Ltd., Similarweb Ltd., Nova

Teva shares surge in early trading after receiving FDA approval for schizophrenia drug
Teva Pharmaceutical shares jumped more than 4% in early trading after the company announced it received FDA approval for WELTRUZA, a drug for treating schizophrenia.
Globes (Hebrew, translated) · 1 month ago · Teva

